Conference Coverage

DANCAVAS misses primary endpoint but hints at benefit from comprehensive CV screening

Publish date: August 27, 2022

 

AT ESC CONGRESS 2022

A version of this article first appeared on Medscape.com.

Pages

Next Article:

Dapagliflozin’s HFpEF benefit recasts heart failure treatment: DELIVER